AURA Aura Biosciences, Inc.
Aura Biosciences, Inc. (AURA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $39.0M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Gibney Anthony S | See Remarks | Sell | 12,824 | $6.42 | $82.3K | 265,354 −4.6% of holding | |
| Sell | 6,922,870 | $5.64 | $39.0M | None left | |||
| Kilroy Conor | See Remarks | Sell | 11,738 | $7.02 | $82.4K | 217,835 −5.1% of holding | |
| de los Pinos Elisabet | See Remarks | Sell | 47,648 | $5.06 | $241.1K | 409,815 −10.4% of holding | |
| Hopkins Janet Jill | Chief Medical Officer | Sell | 20,401 | $5.06 | $103.2K | 232,284 −8.1% of holding | |
| Plavsic Mark | Chief Technology Officer | Sell | 15,890 | $5.05 | $80.2K | 181,397 −8.1% of holding | |
| Kilroy Conor | See Remarks | Sell | 12,079 | $5.05 | $61.0K | 167,234 −6.7% of holding | |
| Elazzouzi Amy | Senior Vice President, Finance | Sell | 8,549 | $5.06 | $43.3K | 75,532 −10.2% of holding | |
| de los Pinos Elisabet | See Remarks | Sell | 16,928 | $4.86 | $82.3K | 457,463 −3.6% of holding | |
| Elazzouzi Amy | Senior Vice President, Finance | Sell | 1,581 | $4.86 | $7.7K | 84,081 −1.8% of holding | |
| Hopkins Janet Jill | Chief Medical Officer | Sell | 17,109 | $5.42 | $92.7K | 252,685 −6.3% of holding | |
| de los Pinos Elisabet | See Remarks | Sell | 9,049 | $6.35 | $57.5K | 474,391 −1.9% of holding | |
| Elazzouzi Amy | Senior Vice President, Finance | Sell | 896 | $6.35 | $5.7K | 85,662 −1% of holding | |
| Plavsic Mark | Chief Technology Officer | Sell | 12,169 | $6.35 | $77.3K | 197,287 −5.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.